Calamos Advisors
PVLA icon

Calamos Advisors’s Palvella Therapeutics PVLA Stock Holding History

Calamos Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.84M Buy
13,361
+2,882
+28% +$427K 0.01% 695
2026
Q2 		$1.6M Buy
10,479
+675
+7% +$81.9K 0.01% 687
2026
Q1 		$1.22M Buy
+9,804
New +$1.02M ﹤0.01% 740

Other funds holding PVLA

Clio Asset Management
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Oak Ridge Investments
Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return
Mitsubishi UFJ Asset Management (UK)
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Aspiriant LLC
Aspiriant LLC Los Angeles, California $4.08B AUM 12.02% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Calamos Advisors's PVLA Position: Q3 2026 in Review

Calamos Advisors increased its Palvella Therapeutics (PVLA) stake by 28% in Q3 2026, buying an estimated $427K and bringing the position to 13,361 shares worth $1.84M. The position accounts for 0.01% of the portfolio, ranked #695.

Calamos Advisors first reported a position in PVLA in Q1 2026 and has held it in 3 quarters since. 44 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Calamos Advisors held 13,361 shares of Palvella Therapeutics worth $1.84M as of Q3 2026.
  • Calamos Advisors bought 2,882 Palvella Therapeutics shares in Q3 2026, an estimated $427K.
  • Palvella Therapeutics made up 0.01% of Calamos Advisors's portfolio in Q3 2026, its #695 holding.
  • Calamos Advisors first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 44 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Calamos Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.